University of Kentucky

UKnowledge
Pathology and Laboratory Medicine Faculty
Publications

Pathology and Laboratory Medicine

11-2008

Technical Variables in High-Throughput miRNA Expression
Profiling: Much Work Remains to Be Done
Peter T. Nelson
University of Kentucky, pnels2@email.uky.edu

Wang-Xia Wang
University of Kentucky, wwangc@uky.edu

Bernard R. Wilfred
University of Kentucky, bernard.wilfred@uky.edu

Guiliang Tang
University of Kentucky, gtang2@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/pathology_facpub
Part of the Neurosciences Commons, Pathology Commons, and the Plant Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Nelson, Peter T.; Wang, Wang-Xia; Wilfred, Bernard R.; and Tang, Guiliang, "Technical Variables in HighThroughput miRNA Expression Profiling: Much Work Remains to Be Done" (2008). Pathology and
Laboratory Medicine Faculty Publications. 27.
https://uknowledge.uky.edu/pathology_facpub/27

This Article is brought to you for free and open access by the Pathology and Laboratory Medicine at UKnowledge. It
has been accepted for inclusion in Pathology and Laboratory Medicine Faculty Publications by an authorized
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Technical Variables in High-Throughput miRNA Expression Profiling: Much Work
Remains to Be Done
Digital Object Identifier (DOI)
https://doi.org/10.1016/j.bbagrm.2008.03.012

Notes/Citation Information
Published in Biochimica et Biophysica Acta -- Gene Regulatory Mechanisms, v. 1779, issue 11, p. 758-765.
Copyright © 2008 Elsevier B.V.
© 2008. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/.

This article is available at UKnowledge: https://uknowledge.uky.edu/pathology_facpub/27

NIH Public Access
Author Manuscript
Biochim Biophys Acta. Author manuscript; available in PMC 2009 November 1.

NIH-PA Author Manuscript

Published in final edited form as:
Biochim Biophys Acta. 2008 November ; 1779(11): 758–765. doi:10.1016/j.bbagrm.2008.03.012.

Technical variables in high-throughput miRNA expression
profiling: much work remains to be done
Peter T. Nelson1, Wang-Xia Wang1, Bernard R. Wilfred1, and Guiliang Tang2
1Department of Pathology and Sanders-Brown Center, University of Kentucky, Lexington, KY 40536
2Department of Plant and Soil Sciences, University of Kentucky, Lexington, KY 40536

Abstract

NIH-PA Author Manuscript

MicroRNA (miRNA) gene expression profiling has provided important insights into plant and animal
biology. However, there has not been ample published work about pitfalls associated with technical
parameters in miRNA gene expression profiling. One source of pertinent information about technical
variables in gene expression profiling is the separate and more well-established literature regarding
mRNA expression profiling. However, many aspects of miRNA biochemistry are unique. For
example, the cellular processing and compartmentation of miRNAs, the differential stability of
specific miRNAs, and aspects of global miRNA expression regulation require specific consideration.
Additional possible sources of systematic bias in miRNA expression studies include the differential
impact of pre-analytical variables, substrate specificity of nucleic acid processing enzymes used in
labeling and amplification, and issues regarding new miRNA discovery and annotation. We conclude
that greater focus on technical parameters is required to bolster the validity, reliability, and cultural
credibility of miRNA gene expression profiling studies.
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Introduction
NIH-PA Author Manuscript

Over the past 5 years, literally dozens of distinct miRNA gene expression profiling platforms
(miGEPs) have been introduced. Studies using miGEPs have helped to establish that miRNA
biology is fundamentally important in plants and animals with clinical implications for human
diseases. Excellent prior reviews have described some of the important aspects of miRNA
profiling (see for example [1–3]). However, research literature to improve quality control for
miGEPs has not developed in parallel. Nor has there been commensurate published work about
the effects of pre-analytical and other technical variables in miRNA gene expression profiling.
The purpose of this review is to describe some technical parameters that may be relevant to
miRNA expression profiling. Unfortunately, there are many stages of a gene expression study
where systematic bias can be introduced. The expression ‘garbage in, garbage out’ can be
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applied to gene expression profiling; however, in the context of high-throughput techniques,
subtle bias can be more problematic than manifestly flawed data. This review is not oriented
toward ‘solving’ technical problems. Instead, we wish to begin bringing important technical
parameters to light because no variable will have the same significance for each miGEP. In
order to not repeat the ‘learning curve’ of the mRNA profiling field, it seems advisable to focus
on technical parameters for the sake of improving the validity and reliability of miRNA gene
expression profiling studies.

Technical variables in gene expression profiling: lessons from mRNAoriented gene expression profiling
General considerations

NIH-PA Author Manuscript

Relative to miRNA studies, mRNA profiling parameters have been assessed over a longer time,
and with greater attention to technical details. Recent reviews of mRNA-related expression
profiling have identified potential sources for systematic biases in expression profiling, along
with strategies to overcome those potential pitfalls [4–6] (see table 1). The initial studies using
high-throughput mRNA profiling microarrays were performed before the technical parameters
for those studies were fully optimized. Hence an appreciation of technical barriers for mRNA
gene expression profiling lagged behind the initial implementation of these techniques. This
is noteworthy because some early mRNA gene expression profiling studies were plagued by
flawed assumptions and non-reproducible results [7,8]. These problems have been manifested
in later years by some degree of skepticism about gene expression profiling results [9]. With
these lessons in mind, it is important to begin addressing these issues soon in the context of
miRNAs.

NIH-PA Author Manuscript

Another general consideration for which mRNA profiling may provide insights for miRNA
profiling is in the cross-comparisons between the results of different gene expression profiling
platforms. In principle, for a given RNA sample, each gene expression profiling platform
should ‘report’ the same repertoire of transcripts. However, this has not been shown necessarily
to be the case (for an excellent review of this literature see [6]). For example, it has been shown
that different cDNA-base mRNA profiling microarray techniques provide differing results,
and these differences are greater when comparing the results between separate laboratories
[6,10–13]. Experimental results tend to vary even more when comparing between less-related
technologies (e.g., microarrays and SAGE) [14–17]. This problem of reproducibility across
platforms renders very difficult any biologically-relevant data mining of public access ‘gene
expression’ databases [18]. Under the most ideal circumstances (within-lab studies performed
in parallel), different gene expression platforms tend to have acceptable agreement as long as
emphasis is placed on the direction of change, rather than the magnitude of change with regard
to differentially expressed genes [19,20].
There has been improvement in recent years in mRNA gene expression profiling—better
experimental design has improved the replicability of expression profiling studies [6]—and
this is largely because the field has focused during that time on technical parameters. A
consensus seems to have emerged that regardless of the gene expression profiling platform,
attention to study design is a key prerequisite to obtaining valid data [6,7,9,21–23]. This focus
has been reflected by a great deal of work, as well as large-scale international consortiums
dedicated to quality control [11,24]. The positive impact that these forward-thinking measures
has had on mRNA expression profiling should have direct implications for researchers
interested in miRNA expression profiling.
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Pre-analytical variables
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The pre-analytical variables that have been most carefully studied in mRNA expression studies
regard the effect of fixation, tissue embedding, freezing and other forms of storage, postmortem interval, RNA amplification, and tissue pH (see for example [25]). These mRNArelated studies will not be reviewed here, partly because there seems to be important differences
between miRNAs and mRNAs in the importance of these parameters. It is also probable that
the effects of particular technical parameters are distinct for different tissue types, so these
results should be interpreted and generalized only with caution.
Relatively few mRNA gene expression studies have addressed systematically the effects of
pre-analytical technical issues as the methods of cell lysis and of RNA isolation. However, the
published studies indicate that standardizing and optimizing RNA isolation techniques, and
the particular manner in which samples are handled, are vitally important to obtaining valid
results in gene expression profiling studies [26–28]. Dell’Orto et al showed that the particular
mRNA isolation technique chosen can impact significantly on the amount of variation within
and between experiments, and that optimizing pre-analytical variables can help to better
demonstrate more accurately which genes are differentially expressed [29]. The importance of
RNA isolation in miRNA studies is discussed below.

NIH-PA Author Manuscript

Depending on the miGEP technique, processing samples after RNA extraction can involve
many additional steps. For example, in order to label and/or amplify nucleic acids, catalysts
are required. Purified proteins such as T4 RNA ligase, poly(A) polymerase, or others are
utilized. These molecules are highly effective usually but are known to have bias with regard
to donor and/or acceptor sequence specificity. To provide a few illustrations, labeling and
amplification steps are predicted to be systematically biased because of the use of T4 RNA
ligase [30,31]. For example, the oligonucleoside electron acceptor C-C-C was ligated by T4
RNA ligase more than three times more efficiently in comparison to the acceptor sequence
ending U-A-G [30]. There is also bias introduced during T7-based RNA amplification (aRNA)
[32]. Thus it has been shown to be problematic to compare between the results of small-sample
and large-sample experiments [33]. Random priming has also been used to label miRNAs,
however, it has been pointed out that the nature of miRNAs (i.e., their short size) may results
in nonrandom labeling [1]. The poly(A) polymerase (PAP) enzyme has been used for direct
RNA dye labeling, with impressive results [1,34], however, it should also be kept in mind that
PAP may also show substrate sequence-related biases [35–37]. These data do not argue against
the usefulness of the ligating, labeling or amplification techniques, which have been well
established (in the context of miRNAs, see for example [38]). However, the potential biases
should be known about and argue strongly for using identical methods in any single study.

NIH-PA Author Manuscript

Note about real-time “quantitative” PCR (RTQPCR)
In either low- or high-throughput format, RTQPCR is an important and widely-used platform
for mature and precursor miRNA expression profiling. RTQPCR is a versatile, sensitive, and
convenient method that provides a numerical read-out of DNA concentration in a sample.
Messenger RNA quantification gives some insights about the validity and reliability of
RTQPCR studies. Much of these data are impressive with regard to the reliability and validity
of the data. However, when evaluated as a group, these studies may be biased toward reporting
positive results. A number of experienced users have raised concerns about the technique. Even
in the best of hands, high-throughput RTQPCR can give variable results in quantifying DNA
as other techniques do, and care must be taken with controls and technical parameters [39–
43]. Accordingly, when carefully compared with microarray and Northern blot results,
RTQPCR results may provide very good but by no means perfect correlation in miRNA
profiling [38,44]. Hence despite its descriptive name, and the fact that RTQPCR has been
repeatedly used as a validation technique of choice (see for example [45–47]), mRNA-related
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studies indicate that it is not necessarily appropriate to use RTQPCR data as an absolute ‘gold
standard’. Like Northern blots and microarrays, RTQPCR is another good but imperfect tool
for nucleic acid quantitation. This is not a criticism of the technique but simply a caveat based
upon experience and supported by the pertinent literature. As concluded by Bustin and Nolan,
“…real-time qPCR is a…powerful technique. But, like anything powerful, it needs to be treated
with respect.” [40]
Technical issues in miRNA expression profiling
Relative to mRNAs, miRNAs are distinguished because of their relatively uniform and small
size, their lack of poly(A) tails, and that they can be represented by very high cellular copy
numbers [48]. Further, the overall mechanism(s) of miRNA function are distinct from mRNAs.
Hence there are special aspects of miRNA biology that need to be taken into account by
researchers interested in miRNA profiling.

MiRNA research is a fast-moving field and produces an evolving set of
technical challenges for miRNA profiling
The study of miRNAs is still in its infancy. The field has grown explosively, with many new
biological paradigms discovered. Researchers interested in miRNA expression profiling
cannot ignore the technical implications of these novel data.

NIH-PA Author Manuscript

At the most basic level, the full complement of miRNAs expressed in most animals including
humans has not been determined. As of December 2007, the Rfam registry (v. 10.1) has
annotated 563 human miRNA genes, an increase from 475 miRNAs in v. 9.2. However, many
of these are identical or nearly-identical paralogs (see http://microrna.sanger.ac.uk/ and Ref.
[49]). It is important to note that certain miRNA assays, including some RTQPCR and some
microarray methods, are highly specific to 3' ending positions of targeting miRNAs. The endposition specificity is considered to represent an advantage of those assays. However, the recent
updates of sequence information, particularly in miRBase changes from v9.2 to v10.0, have
led to changes in the ‘canonical’ end positions of many miRNAs. We have found that many
different 3’ end configurations are represented a given miRNA; for example, Argonaute
proteins-associated hsa-miR-451 has at least seven different 3’ end configurations in human
blood [50]. These differences may indeed lead to different target selectivity for miRNAs. Hence
it may be necessary to incorporate more flexibility into miRNA profiling assays, as was the
case in the microarray studies by Berezikov et al [51].
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In contrast to the official annotated miRNA count, some studies indicate that expressed humans
miRNAs number well over a thousand. For example, a study of human and chimpanzee brains
yielded 447 completely new miRNA genes (see [51–54]). There may be a diminishing return
because the miRNAs described earlier were probably those with the highest expression (see
Figure 2 and Ref [53]). However, the miRNAs that are expressed at low levels in a tissue may
be very important to subpopulations of cells within those tissues (see for example [55]). Seeking
new miRNAs is a challenge because many miRNAs may be expressed preferably during
particular developmental timepoints, or within certain cells or tissues, anatomical subregions,
or environmental conditions. In any case, many current miGEPs survey only several hundred
different miRNAs. For this reason, future miRNA researchers may be compelled to perform
the profiling experiments over again in order to incorporate the many new miRNAs.
Another concern is that the exact biological definition of miRNAs will probably evolve further
in the future. Some miRNAs may have special rules, for example, they may be processed
differently from the current canonical guidelines [56], and unconventional miRNAs are derived
from noncoding RNAs [57–59]). Viruses can either suppress or employ the miRNA pathways
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(see [60–63]). Another twist is that RNA editing, particularly A-to-I conversion, may
dramatically alter miRNA function to the extent of generating a novel miRNA species and/or
altering the degree to which mature miRNAs are produced from the pre-miRNA [64–67].
Furthermore, plant miRNAs and human piRNAs are methylated at the 3’ end [62,68–73], which
may add variables to profiling for 3’ end methylated miRNAs or small RNAs. In principle
these biological ‘tricks’ would be detected by an optimal miRNA profiling platform.

NIH-PA Author Manuscript

Just as with the annotation of new miRNAs, the regulation of miRNA expression is a novel
topic and no doubt many surprises are in store for researchers. A lurking uncertainty relevant
to miGEP experiments is the relationship between the cellular levels of a miRNA in a biological
sample, and that miRNA’s “biological activity”. Analogy can be drawn to messenger RNAs:
mRNAs are templates for the production of polypeptides. However, gene expression is
apparently regulated predominantly post-transcriptionally, so the levels of mRNAs in a
biological sample tend to correlate poorly if at all with protein levels [74]. Likewise, we cannot
query the percentage of miRNA molecules engaged in actively targeting mRNAs. This is a
profound caveat to mRNA based ‘gene expression’ analyses. It is already known that miRNA
function can be affected in cell culture without changing the ‘expression’ (i.e., transcription)
of the miRNA [75]. There may also be regulation of miRNA activity at brain synapses via
proteolytic processing of miRNA processing proteins [76]. Could the detected amount of a
given miRNA correlate poorly in fact with the degree to which that miRNA is actively involved
in regulating target mRNAs? Further work remains to be performed in this area.
Depending upon study design, the distinct characteristics of miRNA biochemistry would be
predicted to impact upon still more aspects of miGEP studies. For example, considerable
miRNA processing occurs in the cytoplasm, where pre-miRNAs are cleaved to produce
‘mature’ ~22nts miRNAs. It is possible that some miGEPs would have difficulty in
differentiating between pre-miRNAs and miRNAs and this would affect the data readout [1].
Some miGEPs have intrinsic advantages in this area because they can detect the sizes and/or
end sequences of small RNAs: miRNA cloning, PCR-based techniques, Northern blots, and
RNA-primed array-based Klenow enzyme (RAKE) microarray techniques (see [51,77–79]).
Many microarray studies have been performed on RNA samples that have been enriched for
small RNAs, or RNA samples that have been cut from PAGE gels, and thus should contain a
high proportion of a given size range of RNAs. However, depending on the RNA isolation
technique, the miGEP platform, and other experimental factors, it is possible that these
techniques may introduce as well as eliminate some systematic biases. For example, whether
or not one spins down the membranous portion of the cell lysate (which may include
nucleoplasm) may strongly influence the relative amount of nuclear-enriched miRNAs.

NIH-PA Author Manuscript

While endonucleolytic processing of miRNAs may affect miGEP results, miRNAs’
heterogeneous spatial distribution is another feature that can influence experimental outcome.
Animal miRNAs are generally considered to localize diffusely within the cytoplasm, within
cytosolic P bodies, stress granules, and/or in association with polyribosomes [80–85]. It has
been established that particular miRNAs tend to be targeted to different cellular compartments.
This can even be true of closely paralogous miRNAs. For example, hsa-miR-29a has been
shown to be targeted to the nucleus, whereas hsa-miR-29b is a predominantly cytoplasmic
human miRNA [86]. These paralogous miRNAs differ only at one central nucleotide and in
several other nucleotides at the 3’ end. In cultured rat neurons, it has been shown that a
particular group of miRNAs is targeted to dendrites, whereas others are more concentrated in
the neuronal soma [87]. These differences could in principle alter the results of miGEPS under
some circumstances. It is possible for example that some cell lysis techniques would be
relatively enriched for cytoplasmic RNA, and thus they would systematically exclude nuclear
miRNAs such as miR-29a.
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As with the spatial processing of cellular miRNAs, the temporal sequence of miRNA
expression may be also subject to complex regulation. MiRNAs were discovered in the context
of worm developmental stages [88–90], and they may play a role in cell fate determination
[91–93]. Hence some miRNAs, within a developmental framework, may exhibit stable and
fixed “on/off” expression pattern. The stability of miRNA expression is supported by the
observation that some unmodified siRNAs are stable and functional for days[94,95] or weeks
[96] in cultured cells. However, new data appears to indicate that certain miRNAs may be a
more dynamic source of biochemical regulation (see for example [85,97–99]), and hence may
exhibit differential stability kinetics and/or rapidly-changing compartmentation in animal cells.
Published data are relatively scanty about rates and mechanism(s) of physiological miRNA
turnover whether in vivo, in vitro, or ex vivo. However, these data will be highly relevant to
miGEP studies. For example, miRNAs are apparently differentially stable during storage, i.e.
some miRNAs are more unstable than others, as quantified using RTQPCR [100]. Surprisingly,
this also extends to miRNAs isolated using Trizol and stored at −80°C [100]. These are exactly
the sort of data that needs to be more known and better understood because there is obvious
potential impact on the work of many researchers.
Clinical/co-morbidity variables
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Human tissue is an important source of RNA for gene expression profiling. Even in relatively
tightly-controlled experimental contexts (surgical pathology biopsy specimens, biopsies from
volunteers, or autopsy series from a closely-followed clinical cohort), there are challenges to
adequate controls in miRNA and mRNA studies alike (see [25]). This is because there are a
wide variety of conditions that can introduce experimental confounds and/or biological
variability. Some of these are presented in Table 2, revised from [25]. Relatively little work
has been performed to probe systematically the importance of premortem clinical features and
co-morbidities, partly because expression profiling is expensive, the variables are so numerous,
and grappling with obstacles of clinical documentation alone is a daunting task.
Some potential confounds may be unexpectedly relevant to human miRNA expression studies.
For example, circadian rhythms are apparently important in cell culture [101–103] as well as
in vivo. Since miRNAs have been shown to be differentially expressed in different circadian
stages [97,104], it seems likely that some of the miGEP results will simply result from
differences in sleep-wake cycle or, biorhythms that can result from various stimuli [103].
Additionally, the importance of particular anesthesia modalities and pain stimuli cause changes
in mammalian mRNA gene expression [105,106], and these data would also be interesting to
correlate with miRNA expression studies. As more studies accumulate it will become easier
to filter these variables. However, for now these potential confounds should be kept in mind.
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Tissue processing
Important variables in tissue processing include tissue procurement, fixation, embedding, and
RNA extraction method. Tissue fixation and embedding are technical parameters where the
unique characteristics of miRNAs have a strong impact on gene expression profiling. This is
evidently explained both by the shortness of the molecules as well as protection from
degradation by intimate RNA-protein interactions. Other factors may be related—miRNA
sequences may have evolved to elude RNA nucleases. Whereas mRNA tends to be labile in
fixed and/or embedded tissue [25], a number of studies have shown robust correlations between
miRNA profiling results in fresh versus in formalin fixed paraffin-embedded (FFPE) tissue
[78,107–110]. Perhaps surprisingly, biologically-relevant profiling data can be obtained from
FFPE tissue that had been stored embedded at room temperature for years [107,108]. However,
it has been noted that RNA isolation from FFPE tissue is far less efficient than from freshfrozen tissue, possibly because of fixative-induced RNA-protein cross-links [110], and the
subtle biases of these reactions have yet to be entirely elucidated. Furthermore, it is possible
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that some miRNAs are relatively less likely to be ‘protected’ via RNA-protein interactions,
and these would be predicted to be more affected by FFPE processing. Or more globally, during
stress [75,111], the overall miRNA-protein pattern may be altered, which may in turn change
the degree to which miRNAs are protected from fixative cross-linking.
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After the tissue sample is obtained, there are many different techniques that can be used to
extract or isolate RNA. Considering the importance to the overall field, relatively little research
has been performed to probe the impact of the particular RNA isolation techniques on miRNA
expression. Different techniques rely on phenol/chloroform extraction, denaturing
polyacrylamide gel electrophoresis (PAGE) with small RNA extraction, and/or column-based
small RNA enrichment. The companion article shows that in human brain isolation for miRNA
microarrays, the different RNA isolation techniques produce results with nontrivial differences
[112]. Since we do not have a current “gold standard”, we do not know which is technically
superior. However, we can certainly recommend that one should never compare samples
against each other that have been isolated using different techniques. It has been noted that
PAGE involves a loss of RNA, although it is unknown whether this can lead to a systematic
bias in miRNA repertoire [1]. Another variable in RNA extraction that goes without saying,
but which is no doubt important, is the expertise of the individual(s) who perform the
experiment. Tissue dissection and RNA extraction can be a challenge to even experienced
individuals. Whether or not an experienced person performs the RNA extraction, it should be
kept in mind that even slight deviations from protocol can induce relatively large changes in
experimental outcome.
Validation (alternative method, in situ hybridization)
Validating the results of miGEP studies is vitally important. As for any high-throughput and
data rich technique, some testable false-positives are to be expected. It is necessary to know if
the differential expression revealed by one platform is also shown using another expression
platform, as this cannot be taken for granted. There is currently no acknowledged ‘gold
standard’ for assessing the concentration of miRNAs in a sample. For example, Northern blots
and RTQPCR have been shown to be very good at quantifying miRNAs, however each can be
problematic in some circumstances [40,78].
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Validation experiments should also extend the tissue-level results (most miGEPs) to the cellular
and subcellular levels, via in situ hybridization (ISH). A number of studies have shown robust
ISH results with miRNAs in a number of different organisms (see [107,113–116]). The insights
from ISH can be vitally important, partly because almost every tissue comprises a variety of
cell types and it is important to know which cells express the miRNA(s) of interest. For
example, in human brain tumors, tissue-level miRNA microarray showed that miR-124
expression was decreased in oligodendrogliomas, whereas the expression of miR-9 was
increased [107]. In situ hybridization revealed that the observed miR-124 decrease was
accurate but not biologically relevant because miR-124 is specific to neurons and neurons are
present in lower density in tissue samples that include brain tumors. By contrast, ISH showed
that miR-9 expression was more robust in tumor cells than normal glial cells, and thus represent
a better candidate for further study in the clinicobiological behavior of brain tumors [107]. We
also found ISH to be an imperative complement to miRNA expression profiling in the study
of Alzheimer’s disease where the cellular localization of miR-107 was important [117].
Another example in which ISH is helpful is in understanding the subcellular distribution of
miRNAs. This principle is illustrated in myocytes where miR- 206 was shown to colocalize
with ribosomes and within cell nucleoli [118]. Finally, ISH can be used to detect biologically
important differences in the distribution of pre-miRNA and mature miRNA species [119].
Thus, ISH data provides a strongly complementary tool in shifting from high-throughput
miGEP experiments to the more focused analyses of individual miRNAs.
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A primary challenge to miGEP studies is to identify miRNA expression changes between
samples that are valid and replicable. Although statistical tools are important in any highthroughput technology, including miGEPs, the statistical tasks to be performed are different.
For most tissues the number of different miRNAs that are highly-expressed is fairly modest:
usually less than a hundred miRNAs are even moderately expressed in a given tissue. Thus the
same emphases that are placed on data management for a very-high throughput mRNA
experiment, in which >100-fold times more transcripts are present, may not be as important to
miRNA studies. MiRNA microarray experiments may align closer with large-scale Northern
blotting than with expression arrays. Furthermore, in our experience, even sensible-seeming
measures such as spiked-in controls must be performed mindful of their own potential for
introducing, rather than dampening, data variability. In any case, the experiments must be
performed considering the underlying biochemistry and the limitations inherent to each
profiling platform.
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Global miRNA expression patterns are thought to change dramatically in response to Drosha
and histone deacetylase levels, cell division status, neoplastic transformation, developmental
stage(s), circadian rhythms, cellular stress, and other factors (see for example [97,104,111,
116,120–124]). Hence the assumptions—common to many mRNA expression profiling
experiments—that overall RNA transcription is ‘constant’, and that a low percentage of
individual transcripts are changed under different test conditions, are not applicable to miRNA
studies. Some informatics, statistical, and normalization issues in miGEPs has been previously
discussed [1]. In short, many researchers employ median scaling normalization (with the caveat
that the results are probably not biologically relevant because global miRNA expression is
changeable) and other means of stabilizing variance with a combination of technical replicates,
logarithmic transformation, with or without spiked-in positive and negative controls [2,125–
128]. Innovative approaches have been employed when reconciling different expression
platforms [129]. However, more work can be performed in order to reconcile miGEP profiling
data analyses with the specifics of miRNA biology.

Conclusion
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In high-throughput miGEP studies, the saying applies: “the devil is in the details”.
Unfortunately, the details for every system (every profiling platform, cell type, disease, and
experimental design) will be distinct. The impact of each technical parameter will hence be
different – however subtly – for each of the profiling platforms. This argues for the need of
more work on the topic of technical parameters in miGEP studies. Yet such papers are not
necessarily considered high-yield in careerist or grantsmanship senses. There is not a high
premium placed on working out details in a given experimental system, much less comparing
different systems in a rigorous way. This problem has no quick fix. Rather, the field must
acknowledge the importance of quality control and implementing measures to ensure that
miGEP results can be considered valid and reliable. The first steps of this process involve the
identification of the different areas of miGEP experiments that can contribute to systematic
bias and/or error. These data begin to provide researchers with the necessary parameters for
designing and implementing rigorous and valid future experiments that can be compared to
each other across the many different miRNA profiling platforms.
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Figure 1.

A chart of the numbers of available papers referent to microarrays, as defined by searches on
the Pubmed database. Papers about mRNA microarrays increased dramatically beginning in
1997, followed by a later increase in the number of papers cross-referenced by the search terms
“microarray” and “quality control”. Papers returned by the search for the terms “microarray”
and “miRNAs” appear to be increasing considerably since first appearing in 2004.
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Figure 2.

A–C. Informative miRNA array results referent to separate brain samples using a cDNA array
after the method of Tang et al [130]. The RNA samples were extracted from gray matter of the
superior and mid-temporal gyri from nondemented elderly autopsy subjects (age and sex
indicated). RNA was then run on a denaturing (urea-PAGE) gel and the small RNA excised,
then labeled with P-32 and hybridized to the cDNA array. Each array element is spotted in
duplicate with miRNAs numbering from top (hsa-miR-1) to bottom (mmu-mir-720). The
extreme bottom right spots are internal spiked-in controls of differing concentrations. The array
elements corresponding to miR-124a are indicated with a diagonal arrow in 1C. Several
observations follow from these results. Firstly, the “signature” of miRNA expression is quite
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consistent across all three arrays. Secondly, in this array that queries 554 different array
elements representing all unique annotated miRNAs (circa spring 2007) found in humans and
mice, ~100 miRNAs are expressed above a moderately-high threshold and several dozen would
be considered highly-expressed. Thirdly, most but not all of the miRNAs detected in these
brain samples were discovered prior to 2005, i.e. annotated before miR-500. An apparently
conspicuous exception to this ‘rule’ is mmu-miR-720, which is indicated with the vertical arrow
at the bottom of 1C. However, a follow-up Northern blot using a probe against mmu-miR-720
is shown in Figure 1D. For the Northern blot, the three different human brain samples were
again used (total RNA isolated using Trizol LS) and run on a 15% urea-PAGE gel. Note that
rather than the expected banding pattern of pre-miRNA and mature miRNA, the miR-720
Northern blot shows that the apparent miR-720 signal is probably not a conventional miRNA.
An anomalous ~50nt RNA band is present (asterisk). Note for comparison the same blot using
a probe for miR-124a which shows the expected pattern of pre-miRNA and mature miRNA.
These results illustrate the importance of confirming array results with another technique, and
shows the strengths of the Northern blot when faced with unexpected array data.
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Table 1

A sample of technical variables shown to play a role in mRNA expression studies
Time between sample removal and RNA

NIH-PA Author Manuscript

isolation
RNA extraction efficiency
Amplification yield
Labeling yield
Hybridization efficiency
Dye bias
Fluorescence gain bias
cDNA array printing pins
Properties of probe plates
Inter-individual differences
Non-linear cross-talk effects
Pooling/non-pooling bias
Genome annotation irregularities
Using correct analytical tools
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Table 2

Clinical variables of potential relevance in miGEP studies on human tissues
Demographics

Age

NIH-PA Author Manuscript

Sex
Race
Genetic factors

Congenital diseases
SNPs
Non-SNP polymorphisms
Mosaicism

'Background' comorbidity (chronic)

Sophistication of clinical documentation
Substance abuse/cigarettes
Prescription drugs/supplements
Metabolic disease
Degenerative processes
Major psychiatric disorder(s)
Inflammatory/infectious disease
Prior sugery/transplant
Radiation therapy
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Body habitus/nutritional status
Toxic/environmental exposures
Organ function: kidney, liver, lungs, etc.
Acute condition

(see above)
Vascular status (blood pressure problem/shock)
External support--respirator, dialysis
Metabolic perturbations
Acute treatment incl chemotherapy, morphine, etc.
State of consciousness incl sleep/wake
Trauma

Related to death/surgery

Single or multi-factorial
Biopsy/autopsy confirmed via pathology
Anesthesia

Preanalytical variables

Post-mortem interval
Interval prior to freezing/fixative
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Tissue pH
Expertise/number of tissue handler(s)
Sophistication of documentation
Detailed information regarding anatomy
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